These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15908203)

  • 1. QSAR analysis of thiazole benzenesulfonamide substituted 3-pyridylethanolamines as beta3-adrenergic receptor agonist.
    Hanumantharao P; Sambasivarao SV; Soni LK; Gupta AK; Kaskhedikar SG
    Bioorg Med Chem Lett; 2005 Jun; 15(12):3167-73. PubMed ID: 15908203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent, selective 3-pyridylethanolamine beta3 adrenergic receptor agonists possessing a thiazole benzenesulfonamide pharmacophore.
    Mathvink RJ; Tolman JS; Chitty D; Candelore MR; Cascieri MA; Colwell LF; Deng L; Feeney WP; Forrest MJ; Hom GJ; MacIntyre DE; Tota L; Wyvratt MJ; Fisher MH; Weber AE
    Bioorg Med Chem Lett; 2000 Sep; 10(17):1971-3. PubMed ID: 10987429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tryptamine-based human beta3-adrenergic receptor agonists. Part 2: SAR of the methylene derivatives.
    Sawa M; Tateishi H; Mizuno K; Harada H; Oue M; Tsujiuchi H; Furutani Y; Kato S
    Bioorg Med Chem Lett; 2004 Dec; 14(24):5963-6. PubMed ID: 15546708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tryptamine-based human beta3-adrenergic receptor agonists. Part 1: SAR studies of the 7-position of the indole ring.
    Mizuno K; Sawa M; Harada H; Tateishi H; Oue M; Tsujiuchi H; Furutani Y; Kato S
    Bioorg Med Chem Lett; 2004 Dec; 14(24):5959-62. PubMed ID: 15546707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a novel, potent and selective human beta3-adrenergic receptor agonist.
    Nakajima Y; Hamashima H; Washizuka K; Tomishima Y; Ohtake H; Imamura E; Miura T; Kayakiri H; Kato M
    Bioorg Med Chem Lett; 2005 Jan; 15(2):251-4. PubMed ID: 15603933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BMS-201620: a selective beta 3 agonist.
    Washburn WN; Sun CQ; Bisacchi G; Wu G; Cheng PT; Sher PM; Ryono D; Gavai AV; Poss K; Girotra RN; McCann PJ; Mikkilineni AB; Dejneka TC; Wang TC; Merchant Z; Morella M; Arbeeny CM; Harper TW; Slusarchyk DA; Skwish S; Russell AD; Allen GT; Tesfamariam B; Frohlich BH; Abboa-Offei BE; Cap M; Waldron TL; George RJ; Young D; Dickinson KE; Seymour AA
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3525-9. PubMed ID: 15177466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4 -[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide.
    Mathvink RJ; Tolman JS; Chitty D; Candelore MR; Cascieri MA; Colwell LF; Deng L; Feeney WP; Forrest MJ; Hom GJ; MacIntyre DE; Miller RR; Stearns RA; Tota L; Wyvratt MJ; Fisher MH; Weber AE
    J Med Chem; 2000 Oct; 43(21):3832-6. PubMed ID: 11052788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of 3D-QSAR models in cyclic ureidobenzenesulfonamides: human beta3-adrenergic receptor agonist.
    Kashaw SK; Rathi L; Mishra P; Saxena AK
    Bioorg Med Chem Lett; 2003 Aug; 13(15):2481-4. PubMed ID: 12852947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A chemoenzymatic scalable route to optically active (R)-1-(pyridin-3-yl)-2-aminoethanol, valuable moiety of beta3-adrenergic receptor agonists.
    Perrone MG; Santandrea E; Giorgio E; Bleve L; Scilimati A; Tortorella P
    Bioorg Med Chem; 2006 Feb; 14(4):1207-14. PubMed ID: 16216512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute effect of L-796568, a novel beta 3-adrenergic receptor agonist, on energy expenditure in obese men.
    van Baak MA; Hul GB; Toubro S; Astrup A; Gottesdiener KM; DeSmet M; Saris WH
    Clin Pharmacol Ther; 2002 Apr; 71(4):272-9. PubMed ID: 11956510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potent and orally bioavailable heterocycle-based beta3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity.
    Lafontaine JA; Day RF; Dibrino J; Hadcock JR; Hargrove DM; Linhares M; Martin KA; Maurer TS; Nardone NA; Tess DA; Dasilva-Jardine P
    Bioorg Med Chem Lett; 2007 Sep; 17(18):5245-50. PubMed ID: 17632003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-Pyridylethanolamines: potent and selective human beta 3 adrenergic receptor agonists.
    Naylor EM; Colandrea VJ; Candelore MR; Cascieri MA; Colwell LF; Deng L; Feeney WP; Forrest MJ; Hom GJ; MacIntyre DE; Strader CD; Tota L; Wang PR; Wyvratt MJ; Fisher MH; Weber AE
    Bioorg Med Chem Lett; 1998 Nov; 8(21):3087-92. PubMed ID: 9873681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive quantitative structure-activity relationships (QSAR) analysis of beta 3-adrenergic ligands.
    Blin N; Federici C; Koscielniak T; Strosberg AD
    Drug Des Discov; 1995 Apr; 12(4):297-311. PubMed ID: 9040990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of the marine sponge derived beta2-adrenoceptor agonist S1319.
    Fairhurst RA; Janus D; Lawrence A
    Org Lett; 2005 Oct; 7(21):4697-700. PubMed ID: 16209513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular modeling of SWR-0342SA, a beta3-selective agonist, with beta1- and beta3-adrenoceptor.
    Ahmed M; Ishiguro M; Nagatomo T
    Life Sci; 2006 Mar; 78(17):2019-23. PubMed ID: 16310810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6.
    Hattori K; Orita M; Toda S; Imanishi M; Itou S; Nakajima Y; Tanabe D; Washizuka K; Araki T; Sakurai M; Matsui S; Imamura E; Ueshima K; Yamamoto T; Yamamoto N; Ishikawa H; Nakano K; Unami N; Hamada K; Matsumura Y; Takamura F
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4679-83. PubMed ID: 19608416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.
    Imanishi M; Tomishima Y; Itou S; Hamashima H; Nakajima Y; Washizuka K; Sakurai M; Matsui S; Imamura E; Ueshima K; Yamamoto T; Yamamoto N; Ishikawa H; Nakano K; Unami N; Hamada K; Matsumura Y; Takamura F; Hattori K
    J Med Chem; 2008 Mar; 51(6):1925-44. PubMed ID: 18307290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent, selective benzenesulfonamide agonists of the human beta 3 adrenergic receptor.
    Weber AE; Mathvink RJ; Perkins L; Hutchins JE; Candelore MR; Tota L; Strader CD; Wyvratt MJ; Fisher MH
    Bioorg Med Chem Lett; 1998 May; 8(9):1101-6. PubMed ID: 9871716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 1,7-cyclized indoles as a new class of potent and highly selective human beta3-adrenergic receptor agonists with high cell permeability.
    Mizuno K; Sawa M; Harada H; Taoka I; Yamashita H; Oue M; Tsujiuchi H; Arai Y; Suzuki S; Furutani Y; Kato S
    Bioorg Med Chem; 2005 Feb; 13(3):855-68. PubMed ID: 15653351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substituted oxazole benzenesulfonamides as potent human beta3 adrenergic receptor agonists.
    Ok HO; Reigle LB; Candelore MR; Cascieri MA; Colwell LF; Deng L; Feeney WP; Forrest MJ; Hom GJ; MacIntyre DE; Strader CD; Tota L; Wang P; Wyvratt MJ; Fisher MH; Weber AE
    Bioorg Med Chem Lett; 2000 Jul; 10(14):1531-4. PubMed ID: 10915043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.